BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

593 related articles for article (PubMed ID: 28111073)

  • 1. Ligand and Target Discovery by Fragment-Based Screening in Human Cells.
    Parker CG; Galmozzi A; Wang Y; Correia BE; Sasaki K; Joslyn CM; Kim AS; Cavallaro CL; Lawrence RM; Johnson SR; Narvaiza I; Saez E; Cravatt BF
    Cell; 2017 Jan; 168(3):527-541.e29. PubMed ID: 28111073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establish an automated flow injection ESI-MS method for the screening of fragment based libraries: Application to Hsp90.
    Riccardi Sirtori F; Caronni D; Colombo M; Dalvit C; Paolucci M; Regazzoni L; Visco C; Fogliatto G
    Eur J Pharm Sci; 2015 Aug; 76():83-94. PubMed ID: 25952103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mass spectrometry for fragment screening.
    Chan DS; Whitehouse AJ; Coyne AG; Abell C
    Essays Biochem; 2017 Nov; 61(5):465-473. PubMed ID: 28986384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of Modulators of Adipocyte Physiology Using Fully Functionalized Fragments.
    Galmozzi A; Parker CG; Kok BP; Cravatt BF; Saez E
    Methods Mol Biol; 2018; 1787():115-127. PubMed ID: 29736714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Large-scale chemoproteomics expedites ligand discovery and predicts ligand behavior in cells.
    Offensperger F; Tin G; Duran-Frigola M; Hahn E; Dobner S; Ende CWA; Strohbach JW; Rukavina A; Brennsteiner V; Ogilvie K; Marella N; Kladnik K; Ciuffa R; Majmudar JD; Field SD; Bensimon A; Ferrari L; Ferrada E; Ng A; Zhang Z; Degliesposti G; Boeszoermenyi A; Martens S; Stanton R; Müller AC; Hannich JT; Hepworth D; Superti-Furga G; Kubicek S; Schenone M; Winter GE
    Science; 2024 Apr; 384(6694):eadk5864. PubMed ID: 38662832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NMR spectroscopy: the swiss army knife of drug discovery.
    Horst R; Farley KA; Kormos BL; Withka JM
    J Biomol NMR; 2020 Nov; 74(10-11):509-519. PubMed ID: 32617727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biophysical screening for the discovery of small-molecule ligands.
    Ciulli A
    Methods Mol Biol; 2013; 1008():357-88. PubMed ID: 23729259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and optimization of PDE10A inhibitors using fragment-based screening by nanocalorimetry and X-ray crystallography.
    Recht MI; Sridhar V; Badger J; Bounaud PY; Logan C; Chie-Leon B; Nienaber V; Torres FE
    J Biomol Screen; 2014 Apr; 19(4):497-507. PubMed ID: 24375910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficiency of hit generation and structural characterization in fragment-based ligand discovery.
    Larsson A; Jansson A; Åberg A; Nordlund P
    Curr Opin Chem Biol; 2011 Aug; 15(4):482-8. PubMed ID: 21724447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fragment-based screening with natural products for novel anti-parasitic disease drug discovery.
    Liu M; Quinn RJ
    Expert Opin Drug Discov; 2019 Dec; 14(12):1283-1295. PubMed ID: 31512943
    [No Abstract]   [Full Text] [Related]  

  • 11. Recent progress in fragment-based lead discovery.
    Schulz MN; Hubbard RE
    Curr Opin Pharmacol; 2009 Oct; 9(5):615-21. PubMed ID: 19477685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Counting on Fragment Based Drug Design Approach for Drug Discovery.
    Kashyap A; Singh PK; Silakari O
    Curr Top Med Chem; 2018; 18(27):2284-2293. PubMed ID: 30499406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fragment Screening by NMR.
    Davis BJ
    Methods Mol Biol; 2021; 2263():247-270. PubMed ID: 33877602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining biophysical screening and X-ray crystallography for fragment-based drug discovery.
    Hennig M; Ruf A; Huber W
    Top Curr Chem; 2012; 317():115-43. PubMed ID: 21837555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Array-Based Ligand Discovery Platform for Proteins With Short Half-Lives.
    Leifer BS; Doyle SK; Richters A; Evans HL; Koehler AN
    Methods Enzymol; 2018; 610():191-218. PubMed ID: 30390799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fragment-based approaches in drug discovery and chemical biology.
    Scott DE; Coyne AG; Hudson SA; Abell C
    Biochemistry; 2012 Jun; 51(25):4990-5003. PubMed ID: 22697260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fragment-based drug discovery and its application to challenging drug targets.
    Price AJ; Howard S; Cons BD
    Essays Biochem; 2017 Nov; 61(5):475-484. PubMed ID: 29118094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Fragment-based lead discovery from smaller fragments to functional ligand].
    Hatayama A; Habashita H
    Tanpakushitsu Kakusan Koso; 2009 Sep; 54(12 Suppl):1611-6. PubMed ID: 21089596
    [No Abstract]   [Full Text] [Related]  

  • 19. Rapid Discovery of Functional Small Molecule Ligands against Proteomic Targets through Library-Against-Library Screening.
    Wu CY; Wang DH; Wang X; Dixon SM; Meng L; Ahadi S; Enter DH; Chen CY; Kato J; Leon LJ; Ramirez LM; Maeda Y; Reis CF; Ribeiro B; Weems B; Kung HJ; Lam KS
    ACS Comb Sci; 2016 Jun; 18(6):320-9. PubMed ID: 27053324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NMR-based platform for fragment-based lead discovery used in screening BRD4-targeted compounds.
    Yu JL; Chen TT; Zhou C; Lian FL; Tang XL; Wen Y; Shen JK; Xu YC; Xiong B; Zhang NX
    Acta Pharmacol Sin; 2016 Jul; 37(7):984-93. PubMed ID: 27238211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.